Press Release Details
Twist Bioscience to Report Fiscal 2018 Fourth Quarter and Full Year Financial Results on Wednesday, December 19, 2018
The call can be accessed by dialing (866) 688-0947 (domestic) or (409)
217-8781 (international) and refer to the conference ID 8279646. A
telephonic replay will be available beginning approximately four hours
after the call through
About
We are a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We are leveraging our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. We are also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. We make products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20181205005243/en/
Source:
Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com